SEC Form 4 · accession 0001127602-17-033930
Elevance Health, Inc. · ELV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Swedish
Officer — Executive Chairman · Director
Period of report
Dec 1, 2017
Accepted (ET)
Dec 5, 2017 · 4:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001156039
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 1, 2017 | M | 21,125 | $67.44 | A | 87,668 | D | |
| Common Stock | Dec 1, 2017 | S | 200 | $227.31 | D | 87,468 | D | |
| Common StockF2 | Dec 1, 2017 | S | 1,100 | $229.13 | D | 86,368 | D | |
| Common StockF3 | Dec 1, 2017 | S | 4,321 | $230.43 | D | 82,047 | D | |
| Common StockF4 | Dec 1, 2017 | S | 7,722 | $231.24 | D | 74,325 | D | |
| Common StockF5 | Dec 1, 2017 | S | 5,882 | $232.08 | D | 68,443 | D | |
| Common StockF6 | Dec 1, 2017 | S | 800 | $233.01 | D | 67,643 | D | |
| Common StockF7 | Dec 1, 2017 | S | 800 | $234.81 | D | 66,843 | D | |
| Common StockF8 | Dec 1, 2017 | S | 300 | $235.67 | D | 66,543 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F9 | $67.44 | Dec 1, 2017 | M | 21,125 | D | — | Apr 1, 2020 | Common Stock | 21,125 | 17,803 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 2, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $228.61 to $229.48. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $229.75 to $230.73. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $230.75 to $231.74. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $231.75 to $232.66. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $232.86 to $233.15. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $234.39 to $235.24. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8This transaction was executed in multiple trades at prices ranging from $235.44 to $235.78. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9The option represents a right to purchase a total of 102,303 shares, and is exercisable in six semi-annual installments, with three installments of 17,050 shares and three installments of 17,051 shares each, beginning on October 1, 2013, which is the six-month anniversary of the option grant date.